



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of the Application of

Isaac Angres et al.

Serial Number: 10/725,405

Filed: December 3, 2003

For: COMPOSITIONS CONTAINING
HMG CoA REDUCTASE
INHIBITORS AND POLICOSANOL

Group Art Unit: 1614

Examiner: Raymond J. Henley III

AFFIDAVIT UNDER 37 C.F.R. § 1.131

STATE OF MARYLAND)
 : SS:
CITY OF GAITHERSBURG)

I, Isaac A. Angres, being duly sworn depose and say:

That I am one the inventors for the above- identified patent application and more specifically, that I am the inventor of claims 1-10, 13, 14, and 17-23;


That I conceived in the United States the invention claimed in the above-identified patent application prior to June 10, 2002, the priority filing date (based on provisional application No. 60/387,463) of the cited U.S. published application No. 2003/0232796 to Cooper et al. Attached Exhibit A is a copy of my notebook pages outlining the original idea of the invention, that is to make formulations containing policosanol and HMG CoA reductase inhibitors such as atorvastatin, mevacor and others mentioned in my laboratory notebook.

That pursuant to this conception, I actually reduced to practice in the United States, the invention claimed in the above-identified patent application prior to June 10, 2002, the priority filing

date (based on provisional application No. 60/387,463) of the cited U.S. published application No. 2003/0232796 to Cooper et al.


That the Exhibit A which relates to the aforementioned conception and actual reduction to practice, corresponds to the invention broadly disclosed and claimed in the above-identified patent application.

Further deponent saith not.

/s/ 
Isaac Albert Angres

Sworn and subscribed to before me this

26 day of November, 2004.



Notary Public

ROBERT M. KOEHLER
Notary Public, Commonwealth of Virginia
My Commission Expires Feb. 29, 2008

Pharmaceutical compositions containing polycosanol and sterols.

The objective is to combine HMG-CoA reductase inhibitors with polycosanol or C20-C39 fatty alcohols. The fatty alcohols inhibit cholesterol synthesis between the formation of acetate and mevalonate.

The HMG-CoA inhibitors include mevastatin,

lovastatin, pravastatin, fluvastatin, simvastatin, rosuvastatin,

cerivastatin, atorvastatin and salts, esters, & lacram and

isomers thereof.

BEST AVAILABLE COPY

Line 100

The following combinations are desirable:

atorvastatin 10mg policosanol 10mg

mevastatin 20mg policosanol 10mg

lovastatin 10mg policosanol 10mg

clivastatin 0.4mg policosanol 10mg

simvastatin 20mg policosanol 10mg

pravastatin 15mg policosanol 5mg

fluvastatin 10mg policosanol 5mg

rosuvastatin 10mg policosanol 5mg

Eric Anger

BEST AVAILABLE COPY